Blood Clot
14
2
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
21%
3 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Inpatient Monitoring of Unfractionated Heparin
Michigan Initial Experience Using Tigertriever for Thrombectomy
Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
PREVENTion of Clot in Orthopaedic Trauma
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
National Vaccine Adverse Event Reporting Survey and Etiology
Gyeongsang National University Hospital Registry
Use of Injectable-platelet-rich-fibrin (I-PRF) to Thicken Gingival Phenotype
Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement.
Noninvasive Measurement of Blood Coagulation
Thrombin Generation in Crohn's Disease
A Prospective Pharmacodynamic Study of Rivaroxaban